公开(公告)号：US11466324B2

公开(公告)日：2022-10-11

申请号：US16248219

申请日：2019-01-15

Applicant: UCB BIOPHARMA SPRL

Inventor： Adam Samuel Platt ,  Stephen Edward Rapecki ,  Mara Fortunato ,  David Robert Rainey ,  Jon Leigh Rundle ,  Paul Alfred Smith ,  Gillian Fairfull Watt

IPC: G01N33/68 ,  C12Q1/6883 ,  C12Q1/6886

Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.

公开(公告)号：US10774152B2

公开(公告)日：2020-09-15

申请号：US15326499

申请日：2015-07-16

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright ,  Kerry Louise Tyson

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/18 ,  C07K16/46

Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

公开(公告)号：US10358493B2

公开(公告)日：2019-07-23

申请号：US15311198

申请日：2015-05-28

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/14 ,  C07K16/46 ,  G01N33/68

Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.

公开(公告)号：US10308723B2

公开(公告)日：2019-06-04

申请号：US15482260

申请日：2017-04-07

Applicant: UCB BIOPHARMA SPRL

Inventor： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki

IPC: A61K39/395 ,  C07K16/46 ,  C07K16/24

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.